Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Yu · SciRah

Researcher profile · Semantic Scholar

H. Yu

Share profile

H. Yu — researcher profile on SciRah

h-index: 54
Works: 213
Citations: 14K

Most-cited papers

Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Á. Quintanal-Villalonga, J. Chan, H. Yu, D. Pe'er +3 more
2020Nature Reviews Clinical Oncology515 citations Open access
Semantic Scholar
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
G. Oxnard, C.-H. J. Yang, H. Yu, Sang We Kim +11 more
2020Annals of Oncology382 citations Open access
Semantic Scholar
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
L. Sequist, Ji-Youn Han, M. Ahn, B. Cho +14 more
2020The Lancet Oncology362 citations Open access
Semantic Scholar
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
A. Schoenfeld, J. Chan, Daisuke Kubota, Hiroki Sato +15 more
2020Clinical Cancer Research340 citations Open access
Semantic Scholar
HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers
Bob T. Li, Flavia Michelini, S. Misale, E. Cocco +45 more
2020Cancer Discovery241 citations Open access
Semantic Scholar
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
H. Yu, Y. Goto, H. Hayashi, E. Felip +25 more
2023Journal of Clinical Oncology223 citations Open access
Semantic Scholar
Precision Medicine in Non-Small Cell Lung Cancer: Current Applications and Future Directions.
Soo-Ryum Yang, A. Schultheis, H. Yu, D. Mandelker +2 more
2020Seminars in Cancer Biology201 citations
Semantic Scholar
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
P. Jänne, C. Baik, Wu-Chou Su, M. Johnson +17 more
2021Cancer Discovery196 citations Open access
Semantic Scholar
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
R. Hartmaier, A. Markovets, M. Ahn, L. Sequist +16 more
2022Cancer Discovery170 citations Open access
Semantic Scholar
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
J. Jee, E. Lebow, R. Yeh, J. Das +68 more
2022Nature Medicine159 citations Open access
Semantic Scholar
Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation
Á. Quintanal-Villalonga, H. Taniguchi, Ying-Qian A. Zhan, Maysun M. Hasan +32 more
2020bioRxiv158 citations Open access
Semantic Scholar
Targeting Aurora B Kinase Prevents and Overcomes Resistance to EGFR Inhibitors in Lung Cancer by Enhancing BIM- and PUMA-mediated Apoptosis
Kosuke Tanaka, H. Yu, Shao-Hui Yang, Song Han +16 more
2021Cancer Cell142 citations Open access
Semantic Scholar
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
H. Yu, A. Schoenfeld, A. Makhnin, R. Kim +17 more
2020JAMA Oncology115 citations Open access
Semantic Scholar
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer
K. Arbour, H. Rizvi, A. Plodkowski, M. Hellmann +9 more
2021Clinical Cancer Research105 citations Open access
Semantic Scholar
Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
N. Choudhury, A. Marra, J. Sui, J. Flynn +15 more
2022Journal of Thoracic Oncology104 citations Open access
Semantic Scholar
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.
J. Osorio, K. Arbour, D. Le, J. Durham +13 more
2019Journal of Clinical Oncology93 citations Open access
Semantic Scholar
Clinical Trial of Proton Craniospinal Irradiation for Leptomeningeal Metastases.
T. Yang, N. Wijetunga, J. Yamada, S. Wolden +17 more
2020Neuro-Oncology88 citations Open access
Semantic Scholar
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
Á. Quintanal-Villalonga, H. Taniguchi, Ying-Qian A. Zhan, Maysun M. Hasan +26 more
2021Journal of Hematology & Oncology75 citations Open access
Semantic Scholar
Biomarker-directed Phase II Platform Study in Patients with EGFR Sensitizing Mutation-positive Advanced/Metastatic Non-small Cell Lung Cancer Whose Disease has Progressed on First-line Osimertinib Therapy (ORCHARD)
H. Yu, S. Goldberg, X. Le, Z. Piotrowska +16 more
2021Clinical Lung Cancer70 citations Open access
Semantic Scholar
Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset
C. Febres-Aldana, Jason C. Chang, R. Ptashkin, Yuhan Wang +13 more
2022Clinical Cancer Research67 citations Open access
Semantic Scholar
Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis
A. Skakodub, H. Walch, K. Tringale, J. Eichholz +13 more
2023Nature Communications61 citations Open access
Semantic Scholar
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
Irene Braña, G. Shapiro, M. Johnson, H. Yu +11 more
202158 citations
Semantic Scholar
The Evolving Landscape of Resistance to Osimertinib.
A. Schoenfeld, H. Yu
2020Journal of Thoracic Oncology58 citations Open access
Semantic Scholar
Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions
N. Choudhury, A. Schoenfeld, J. Flynn, C. Falcon +8 more
2021Clinical Cancer Research57 citations Open access
Semantic Scholar
Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer
Anup K Biswas, S. Han, Yi-Fan Tai, Wan-Chao Ma +19 more
2022Cancer Discovery56 citations Open access
Semantic Scholar
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Z. Piotrowska, D. S. Tan, E. Smit, A. Spira +11 more
2023Journal of Clinical Oncology48 citations Open access
Semantic Scholar
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Á. Quintanal-Villalonga, V. Durani, A. Sabet, E. Redin +21 more
2023Science Translational Medicine48 citations Open access
Semantic Scholar
Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies
N. Myall, H. Yu, S. Soltys, H. Wakelee +1 more
2021Neuro-Oncology Advances48 citations Open access
Semantic Scholar
Clinical experience of cerebrospinal fluid-based liquid biopsy demonstrates superiority of cell free DNA over cell pellet genomic DNA for molecular profiling.
T. Bale, Soo-Ryum Yang, James P. Solomon, K. Nafa +21 more
2021Journal of Molecular Diagnostics44 citations Open access
Semantic Scholar
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells
Moiez Ali, Min Lu, H. Ang, R. Soderquist +13 more
2022Science Translational Medicine42 citations Open access
Semantic Scholar
Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer
H. Yu, L. Paz-Ares, J. Yang, K. Lee +10 more
2020Clinical Cancer Research40 citations Open access
Semantic Scholar
Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
J. Rotow, J. Patel, M. Hanley, H. Yu +14 more
2023Clinical Cancer Research39 citations Open access
Semantic Scholar
Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
M. J. Grant, J. Aredo, J. Starrett, P. Stockhammer +17 more
2023Clinical Cancer Research36 citations Open access
Semantic Scholar
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
Kamrine E. Poels, A. Schoenfeld, A. Makhnin, Y. Tobi +11 more
2021Nature Communications33 citations Open access
Semantic Scholar
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib: a Brief Report
G. Castellano, J. Aisner, S. Burley, Brinda K. Vallat +3 more
2019Journal of Thoracic Oncology32 citations Open access
Semantic Scholar
Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.
A. Schoenfeld, J. Chan, H. Rizvi, N. Rekhtman +10 more
2019Journal of Clinical Oncology31 citations
Semantic Scholar
Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).
H. Yu, D. S. Tan, E. Smit, A. Spira +13 more
2022Journal of Clinical Oncology28 citations
Semantic Scholar
Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).
Z. Piotrowska, H. Yu, J. Yang, M. Koczywas +14 more
2021Journal of Clinical Oncology28 citations
Semantic Scholar
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
A. J. Piper-Vallillo, J. Rotow, J. Aredo, K. Shaverdashvili +13 more
2022JTO Clinical and Research Reports27 citations Open access
Semantic Scholar
Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis
N. Wijetunga, A. Boire, R. Young, Y. Yamada +10 more
2021Neuro-Oncology Advances26 citations Open access
Semantic Scholar
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
H. Yu, Jie Yang, H. Hayashi, Y. Goto +9 more
2023Future Oncology25 citations Open access
Semantic Scholar
FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
J. Rotow, J. Patel, M. Hanley, H. Yu +11 more
202124 citations Open access
Semantic Scholar
Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
H. Yu, Myung-Ju Ahn, Sang-We Kim, B. Cho +7 more
2019Clinical Trials24 citations
Semantic Scholar
Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.
P. Jänne, H. Yu, M. Johnson, C. Steuer +5 more
2019Journal of Clinical Oncology24 citations
Semantic Scholar
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
P. Janne, C. Baik, Wu-Chou Su, M. Johnson +16 more
202123 citations
Semantic Scholar
Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.
H. Yu, K. Kerr, C. Rolfo, Jian Fang +16 more
2023Journal of Clinical Oncology22 citations Open access
Semantic Scholar
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers
Y. Murciano-Goroff, T. Pak, S. Mondaca, J. Flynn +20 more
2021British Journal of Cancer22 citations Open access
Semantic Scholar
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.
M. Johnson, Jason T. Henry, A. Spira, J. Battiste +10 more
2023Journal of Clinical Oncology18 citations Open access
Semantic Scholar
LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
H. Yu, C. Baik, K. Gold, H. Hayashi +13 more
202018 citations Open access
Semantic Scholar
Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers
Hiroki Sato, M. Offin, Daisuke Kubota, H. Yu +5 more
2020Journal of Thoracic Oncology16 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Kris×15
Invite
M. Kris — researcher profile on SciRah
C. Rudin×12
Invite
C. Rudin — researcher profile on SciRah
M. Ladanyi×11
Invite
M. Ladanyi — researcher profile on SciRah
Gregory Riely×10
Invite
Gregory Riely — researcher profile on SciRah

×8

Invite

M. Offin — researcher profile on SciRah

Invite

M. Arcila — researcher profile on SciRah

Invite

N. Rekhtman — researcher profile on SciRah

A. Schoenfeld×7

Invite

A. Schoenfeld — researcher profile on SciRah

Invite

M. Johnson — researcher profile on SciRah

Invite

J. Yang — researcher profile on SciRah

Invite

H. Rizvi — researcher profile on SciRah

Invite

M. Koczywas — researcher profile on SciRah